Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 5, 2014, Pages 369-380

  Drollmann, Anton ^a   Brown, Matthew ^b   Sechaud, Romain ^a   Perry, Sheryl ^b   Hara, Hisanori ^a   Jones, Ieuan ^a   Febbraro, Salvatore ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Institutes for Biomedical Research   (United States)

^c Simbec Altasciences   (United Kingdom)

Author keywords

Fixed dose combination; Healthy volunteers; Pharmacodynamics; Pharmacokinetic; Randomized

Indexed keywords

GLUCOSE; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; PLACEBO; POTASSIUM; SALMETEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INHALER; LACERATION; LIP PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; OROPHARYNX PAIN; PAIN; POTASSIUM BLOOD LEVEL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; RISK ASSESSMENT; SHORT COURSE THERAPY; SOFT TISSUE INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; BLOOD GLUCOSE; BRONCHI; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLYCOPYRROLATE; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; INDANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SAFETY; POTASSIUM; QUINOLONES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84900458669     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202034     Document Type: Article

References (36)

1. Global Strategy for the Diagnosis. Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org. [accessed February 19, 2013].
2. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361: 449-456. CrossRef PubMed (Pubitemid 36173708)
3. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, Matera MG. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004; 98: 1214-1221. CrossRef PubMed (Pubitemid 39497224)
4. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008; 134: 255-262. CrossRef PubMed
5. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012; 21: 101-108. CrossRef PubMed
6. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005; 26: 214-222. CrossRef PubMed (Pubitemid 41079064)
7. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006; 129: 509-517. CrossRef PubMed
8. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011; 37: 273-279. CrossRef PubMed
9. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011; 105: 719-726. CrossRef PubMed
10. Kerwin E, Hébert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012; 40: 1106-1114. CrossRef PubMed
11. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65: 473-479. CrossRef PubMed
12. D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011; 12: 156. CrossRef PubMed
13. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012; 7: 503-513. CrossRef PubMed
14. Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD. 2010; 7: 418-427. CrossRef PubMed
15. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010; 65: 1086-1091. CrossRef PubMed
16. Bateman ED, Ferguson GT, Barnes N, Gallager N, Green Y, Henley M, Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: The SHINE study. Eur Respir J. 2013; published online ahead of print: doi:10.1183/09031936.00200212.
17. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VKT, D'Andrea P, Chen H, Banerji D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013; 1: 51-60. CrossRef PubMed
18. Mahler DA, Decramer M, D'Urzo AD, Worth H, White T, Alagappan V, Gallagher N, Chen H, Kulich K, Banerji D. Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study. Am J Respir Crit Care Med. 2013; 187: A6070.
19. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013; 1: 199-209. CrossRef PubMed
20. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002; 165: 1353-1358. CrossRef PubMed (Pubitemid 34522936)
21. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011; 6: 477-492. CrossRef PubMed
22. Groenwold RH, Klungel OH, Grobbee DE, Hoes AW. Selection of confounding variables should not be based on observed associations with exposure. Eur J Epidemiol. 2011; 26: 589-593. CrossRef PubMed
23. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006; 144: 904-912. CrossRef PubMed (Pubitemid 46768131)
24. Harvey RD, Belevych AE. Muscarinic regulation of cardiac ion channels. Br J Pharmacol. 2003; 139: 1074-1084. CrossRef PubMed (Pubitemid 36920669)
25. Giachetti A, Micheletti R, Montagna E. Cardioselective profile of AF-DX 116, a muscarine M2 receptor antagonist. Life Sci. 1986; 38: 1663-1672. CrossRef PubMed (Pubitemid 16072423)
26. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004; 125: 2309-2321. CrossRef PubMed (Pubitemid 38796452)
27. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300: 1439-1450. CrossRef PubMed
28. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med. 2000; 161: 827-830. CrossRef PubMed (Pubitemid 30171738)
29. Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ. Nebulised salbutamol and angina. Br Med J (Clin Res Ed). 1982; 285: 796-797. CrossRef PubMed (Pubitemid 12058145)
30. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008; 149: 380-390. CrossRef PubMed
31. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010; 65: 719-725. CrossRef PubMed
32. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180: 948-955. CrossRef PubMed
33. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011; 105: 571-579. CrossRef PubMed
34. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993; 60: 405-430. CrossRef PubMed
35. Khindri S, Sabo R, Harris S, Woessner R, Jennings S, Drollmann AF. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med. 2011; 11: 31. CrossRef PubMed
36. Poller U, Nedelka G, Radke J, Pönicke K, Brodde OE. Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers. J Am Coll Cardiol. 1997; 29: 187-193. CrossRef PubMed The study was funded by Novartis. AD, MB, RS, SP, HH, and IJ are employees of Novartis. (Pubitemid 27028738)